Recursion Pharmaceutical

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

The field of cancer treatment has long struggled with the immense costs and time-consuming nature of drug development. Traditional methods often take over a decade and billions of dollars to bring a single drug to market,

The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years,

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

Telescope Innovations Corp. (CSE:TELI) is leveraging its expertise to advance chemistry process development and crystallization optimization in pharmaceuticals, industrial chemicals, and critical minerals ・Telescope's Self-Driving Labs (SDLs) integrate AI,

Cathie Wood says most profound application of AI is in healthcare. She particularly expects Recursion Pharma and Illumina to benefit from AI.